GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

NCT05819658 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: GV1001 Placebo
DRUG: GV1001 0.56mg
DRUG: GV1001 1.12mg

Sponsor

GemVax & Kael